Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
Dumessa Edessa,1 Mekonnen Sisay2 1Department of Pharmacy Practice, 2Department of Pharmacology and Toxicology, School of Pharmacy, College of Health and Medical Sciences, Haramaya University, Oromia, Ethiopia Abstract: In normal cell cycle progression, transition of G0/G1 phase to synthesis (S) phas...
Saved in:
Main Authors: | Edessa D, Sisay M |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/adb89baa8dbc4a39a078e6ab110d38ab |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
by: Iorfida M, et al.
Published: (2020) -
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
by: Irina V. Kolyadina, et al.
Published: (2021) -
Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
by: Board Editorial
Published: (2021) -
Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
by: Editorial Board
Published: (2021) -
The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
by: Emily Jiggens, et al.
Published: (2021)